GLP1R and type 2 diabetes mellitus: We expect the benefit of sitagliptin treatment to be associated with higher intact GLP-1 (active form) levels due to inactivation of DPP-4i, as already demonstrated in patients with T2DM after very short-term treatment with sitagliptin (19,20).